Efruxifermin Demonstrates Promising 96-Week Efficacy and Safety in Treating Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase 2b HARMONY Trial
The HARMONY trial reveals that once-weekly efruxifermin significantly improves liver fibrosis without worsening MASH over 96 weeks, with a favorable safety profile supporting its phase 3 evaluation.
